A2A Pharmaceuticals has a TACC3 inhibitor in phase 1 for ovarian, triple negative and endometrial cancers. Based on complete regressions preclinically, for these indications as well as gastric and prostate cancer, the IND will be expanded.
DepMap work done by A2A showed TACC3 to be highly selective/highly selective. This was a year ago. It’s not clear why DepMap has not updated it yet.
I’m not sure I understand your question.
When you say, “DepMap work done by A2A showed TACC3 to be highly selective/highly selective” are you saying that the DepMap project was collaborating with A2A Pharmaceuticals in some way?
Or are you referring to the more general concept of DepMap, performing CRISPR screens to identify targets, was done by A2A?
I just looked at the gene page for TACC3, and the CRISPR data we have in the portal supports the the statement that this gene meets the criteria we defined for “Strongly selective essential”
When you say DepMap has not updated it, what update are you looking for?
Thanks,
Phil
Our understanding is that a significant number of cell lines have not been updated. If those cell lines are uodated then DepMap would show TACC3 as being strongly selective rather than highly selective/common essential.
Edward Painter
914 841 8818
